Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PHAT by emailGet an email when PHAT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PHAT, unsubscribe in one click. Privacy
📣 What PHAT Says Is Next
fourth quarter of 2026 · “Topline results from the 12-week blinded treatment portion of the trial are expected during the fourth quarter of 2026.”
Company press release, Jul 30, 2026 · SEC filing
fourth quarter of 2026 · “First subject enrollment for the planned Phase 3 trial is expected during the fourth quarter of 2026.”
Company press release, Jul 30, 2026 · SEC filing
second half of 2026 · ““Our more moderate revenue guidance still reflects meaningful growth in the second half of 2026.” Recent Business Highlights and Second Quarter 2026 Results VOQUEZNA Commercial Progress:”
Company press release, Jul 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PHAT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHAT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.